We are developing novel therapies and groundbreaking early diagnostics for the hundreds of millions of people in underserved populations worldwide who endure painful diseases with no treatment options — and have no voice in their own care.
A pipeline of synergistic, highly differentiated diagnostic and drug candidates leveraging our novel cellular metabolism approach.pipeline
A single dose therapy that
inhibits fibrotic tissue growth at
the surgical site.
A panel of biomarker tests that
result in earlier detection, enabling early-stage treatment.
Our non-invasive biomarker test detects ovarian tumors at earlier stages, promoting better outcomes.
We see health and wellness from the patient's perspective. That’s why we’re developing holistic treatments to detect and treat disease while nurturing overall wellbeing. Our goal? To break through the disparities that exist across gender, race, culture, and geography as we deliver the care and compassion you deserve.
The latest updates and insights from Temple Therapeutics.See all
Rope-like bands of internal scar tissue that form in 70-90% of patients who undergo abdominal surgery have bedeviled patients and surgeons since medical literature history’s recording of adhesions in 1836read
LMTK3 as prognostic marker for ovarian cancer and TTX335o, award-winning drug candidate with tumor-killing activity, presented as game-changing treatment for womenread
Attempts to overcome drug resistance are central to both clinical and basic molecular research in cancer chemotherapy.read
This article is not like my previous blogs. This one is more research orientated and somehow I believe in this one strongly.read
Register to receive the latest news and insights from Temple Therapeutics.